www.fdanews.com/articles/202894-guardants-liquid-biopsy-test-receives-fda-approval-for-jjs-rybrevant
Guardant’s Liquid Biopsy Test Receives FDA Approval for J&J’s Rybrevant
May 25, 2021
Guardant Health’s CDx liquid biopsy test has been approved by the FDA for use as the first companion diagnostic for Johnson & Johnson’s (J&J) lung cancer drug Rybrevant (amivantamab-vmjw).
The test will be used to profile tumor mutations and to identify patients potentially eligible for Rybrevant. The drug was recently approved for locally advanced or metastatic nonsmall-cell lung cancer with epidermal growth factor receptor exon 20 insertion mutation after disease progression during or after platinum-based chemotherapy.
Oncologists can use the test to obtain comprehensive genomic results from a blood sample in seven days.